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ABSTRACT 
Objective: The aim of the present study was to prepare and optimize levamisole chewable tablets by using various super disintegrants, namely; 
sodium starch glycolate, DRC Indion 204, and DRC Indion 234. 
Methods: Drug excipient compatibility study was carried out by FTIR spectroscopy to verify the compatibility of levamisole with the excipients. 
Nine batches of levamisole chewable tablets were prepared according to 32
Results: FTIR study revealed that the excipients used in the formulations were compatible with the drug. The pre-compression and post-
compression parameters were found within the IP limits. Form the dissolution studies, it was evident that the formulation prepared with DRC 
Indion 234 (50 mg) showed maximum percentage drug release in 45 min (97.13%) hence it is considered as optimized formulation. When 
compared to all other formulation, the batches with DRC Indion 234 (F7-F9) showed a better release of the drug (90 % drug release within 45 min).  
 factorial designs using a direct compression method by optimizing the 
super disintegrant concentration. The powder blend was exposed to pre-compression studies of the powder blend followed by post-compression 
studies of the formulated tablets.  
Conclusion: Nine batches of levamisole chewable tablets were successfully formulated by optimizing the concentration of super disintegrants such 
as sodium starch glycolate, DRC Indion 204, and DRC Indion 234. It was concluded from the dissolution studies that the DRC Indion 234 is the best 
super disintegrant irrespective of their concentration for the formulation of levamisole chewable tablets when compared to sodium starch Glycolate 
and DRC Indion 204. 
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In allopathic medicine system, tablets are still the best oral dosage 
form due to their ease of administration. The chewable tablet dosage 
forms continue to draw attention in the search for improved patient 
compliance and also to enhance the therapeutic effectiveness of the 
drug. Ideally, chewable tablets offer a therapeutic concentration of 
the drug in the blood, which is maintained throughout the dosing 
interval with a reduction of fluctuation in the concentration. The 
chewable tablets mainly intended for children or adults who may 
have difficulty in swallowing a tablet intact [1]. These tablets are 
required to be chewed in between the teeth before its consumption 
[2]. The chewable tablets are disintegrated in the mouth upon 
chewing and can be swallowed with or without the use of water as 
per the patient’s compliance. The ingredients disintegrated and 
released because of chewing, absorbed from the stomach, which can 
reduce the lag time of absorption. To enhance the palatability of the 
tablet, natural or synthetic sweeteners, colorants, and fruity 
flavoring agents are commonly used in the tablets [3, 4]. Among the 
tablet excipients, super disintegrants are often considered as the 
most important excipient in orodispersible tablets as they make 
quick disintegration of the drug into its fragments upon ingestion, to 
allow the onset of drug dissolution and eventual absorption. The 
disintegration process can mechanistically be explained as a two-
step process i.e., breakdown into coarse aggregates followed by 
subsequent disaggregation into fine primary particles. In the present 
work, a super disintegrant addition method at low, medium, and 
high level was employed. 
A survey on the literature indicates that extensive work was 
conducted in the development of the chewable tablet. Some of the 
drugs studied include albendazole [5, 6], acetaminophen [7], 
antibiotics [8], caffeine [9], montelucast sodium [10], darunavir [11], 
clarythromycin [12]. In this present investigation, levamisole, a 
synthetic imidazo-thiazole derivative [13, 14], an anthelmintic used 
in the treatment of worm infection [15, 16], is selected as a drug of 
choice. The bioavailability levamisole is low (47%) with a half-life of 
4.4-5.6 h [17, 18]. In this study, an attempt has been made to prepare 
levamisole chewable tablets by optimizing the concentration of 
super disintegrants such as sodium starch glycolate, DRC Indion 204, 
and DRC Indion 234. 
MATERIALS AND METHODS 
Material 
Levamisole and all other excipients such as sodium starch glycolate, 
DRC indion 204, DRC indion 234, talc, magnesium stearate, and 
microcrystalline cellulose (Avicel 101) were purchased from Natco 
Pharma Pvt. Ltd. All the chemicals and reagents used in the study 
were of analytical grade. 
Method 
Formulation of levamisole chewable tablet by direct 
compression method 
Levamisole chewable tablets were prepared by direct compression 
method. Based on the availability of the super disintegrants in the 
laboratory, three super disintegrants namely sodium starch 
glycolate, DRC Indion 204, and DRC Indion 234, were selected for 
this study. All the ingredients were accurately weighed and passed 
through a standard sieve (sieve no.60). The required quantity of 
drug and excipient were mixed thoroughly in a polybag by geometric 
addition method for 20 min. The obtained powder blend was then 
compressed, with a 4.5 tons compression force, using rotary tablet 
machine-8 station with 9 mm flat punch, B tooling. Nine batches (F1-
F9
 
) of levamisole tablets, having an average of 300 mg, with relative 
density (solid fraction) less than 1 for all the batches, were obtained 
[19]. Composition of preliminary trials for levamisole chewable 
tablets by direct compression is shown in table 1. 
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Table 1: Formulation of levamisole chewable tablets 
Ingredients F* F1 F2 F3 F4 F5 F6 F7 F8 9 
Levamisole 50 50 50 50 50 50 50 50 50 
Sodium Starch Glycolate 50 75 100 - - - - - - 
DRC Indion 204 - - - 50 75 100 - - - 
DRC Indion 234 - - - - - - 50 75 100 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Magnesium Stearate 2.5 2.5 2.5 2 2.5 2.5 2.5 2.5 2.5 
Microcystalline Cellulose Qs Qs Qs Qs Qs Qs Qs Qs Qs 
Total 300 300 300 300 300 300 300 300 300 
*All ingredients are expressed in mg only, Qs: Quantity sufficient to 300 mg  
 
Determination OF UV absorption maxima 
Levamisole solution was prepared in phosphate buffer pH 6.8 and 
diluted suitably. The UV spectrum of the solution was taken on Lab 
India 3200 UV/Vis double beam Spectrophotometer. The Solution 
exhibited UV maxima at 220 nm. 
Preparation of standard calibration curve of levamisole 
100 mg of levamisole was accurately weighed and dissolved in a 
little amount of methanol and made up the final volume up to 100 ml 
with phosphate buffer pH 6.8 to prepare a stock solution. The 10 ml 
of stock solution was further diluted with phosphate buffer pH 6.8 in 
100 ml to get a 100 μg/ml solution (working standard). Then 2, 4, 6, 
8 and 10 ml of working standard was taken in 10 ml standard 
volumetric flask and made up the volume with phosphate buffer pH 
6.8 to prepare 2μg, 4μg, 6μg, 8μg, and 10μg drug per ml solution. 
Then the absorbance was measured in a UV spectrophotometer at 
220 nm against phosphate buffer pH 6.8 as blank. 
Drug-excipient compatibility studies 
The compatibility between the pure drug and excipients were 
detected by FTIR spectra obtained on Bruker FTIR Germany (Alpha 
T). The potassium bromide pellets were prepared on KBr press by 
grounding the solid powder sample with 100 times the quantity of 
KBr in a mortar. The finely grounded powder was then introduced 
into a stainless steel die and was compressed between polished steel 
anvils at a pressure of about 8t/in2. The spectra were recorded over 
the wavenumber of 8000 to 400 cm-1
Evaluation of pre-compression parameters of the powder blend  
. 
Loose bulk density (LBD) 
LBD was measured by pouring the powder blend (passed through 
standard sieve # 20) into a measuring cylinder and the weight was 
noted without disturbing the cylinder. The LBD is calculated 
according to the formula mentioned below [20]. It is expressed in 
gm/cm2
 blendpowder   theof Volume / blendpowder   theof Mass = LBD
 and is given by;  
 
Tapped bulk density (TBD) 
It is the ratio of the total mass of the powder to the tapped volume of the 
powder. Volume was measured by tapping the powder for 750 times 
and the tapped volume was noted if the difference between these two 
volumes is less than 2%. If it is more than 2%, tapping is continued for 
1250 times and tapped volume was noted. Tapping was continued until 
the difference between successive volumes is less than 2 % (in a bulk 
density apparatus). It is expressed in gm/cm2
powder  theof  volumeedblend/Tapppowder   theof Weight = TBD
 and is given by;  
 
Angle of repose  
The friction forces in a loose powder can be measured by the angle 
of repose (Ө). It is defined as the “maximum angle possible between 
the surface of the pile of powder and the horizontal plane”. The 
powder mixture was allowed to flow through the funnel fixed to a 
stand at a definite height. The angle of repose was then calculated by 
measuring the height and the radius of the heap of powder formed. 
Care was taken to see that the powder particles slip and roll over 
each other through the sides of the funnel [21, 22]. The angle of 
repose is calculated by the following formula;  
(h/r) = )(Tan θ  
  (h/r) 1Tan = -θ  
Where, Ө= Angle of repose, h = Height in cm, r = Radius in cm 
Carr’s index 
Based on loose and tapped bulk density, the percentage 
compressibility of the powder blend was determined. It is calculated 
by the following formula;  
100/TBD × LBD) - (TBD =index  sCarr'  
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of powder flow. It is 
calculated by the following formula;  
TBD/LBD = ratio sHausner'  
Evaluation of levamisole chewable tablets 
Weight variation 
20 tablets were selected randomly from the lot and weighted 
individually to check for weight variation. The percentage deviations 
from the mean value were calculated by using the following equation 
[23-28]; 
100%. ×  W2)/W2]- [(W1 =iation Weight var  
Where W1 
W
= Initial weight of the tablet 
2 
Hardness 
= Average weight of the tablet 
Testing the hardness of a tablet will reveal the resistance of a tablet 
for chipping and breakage while transporting [29]. Hardness or 
tablet crushing strength (fc) is the force required to break a tablet in 
a diametric compression. It was measured using the Monsanto tablet 
hardness tester. It is expressed in kg/cm2
Thickness  
. 
Ten tablets were selected randomly from each batch and thickness 
was measured by using Vernier Caliper. 
Friability 
Friability of the tablet determined using Roche friabilator. This 
device subjects the tablet to the combined effect of abrasion and 
shock in a plastic chamber revolving at 25 rpm and dropping a tablet 
at the height of 6 inches in each revolution. The pre-weighed sample 
of tablets was placed in the friabilator and was subjected to the 100 
revolutions. Tablets were dusted using a soft muslin cloth and 
reweighed. The friability (F) is given by the formula;  
 
Drug content uniformity 
10 tablets were weighed and triturated from each batch. The tablet 
triturates equivalent to 10 mg of the drug was accurately weighed 
and shaken for 30 min to get dissolved in 100 ml of phosphate buffer 
(pH 6.8). Later the solutions were filtered and further dilutions were 
made with phosphate buffer (pH 6.8). Then the absorbance was 
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taken at 220 nm against the blank, and the concentration of 
levamisole in each batch was determined. 
In vitro dissolution studies 
USP II Paddle apparatus was used to determine the drug release of 
levamisole from the chewable tablets. The phosphate buffer (pH 6.8, 
500 ml) was used as a dissolution medium. The paddle was allowed 
to rotate at 50 rpm with maintaining the temperature at 37±0.5 °C. 
The samples were withdrawn at specific intervals and the drug 
concentration was analyzed by UV spectrophotometer at 220 nm. 
RESULTS AND DISCUSSION 
Standard calibration curve of levamisole 
Data for the standard plot of levamisole in phosphate buffer (pH 6.8) is 
shown in table 2. It was found that the estimation of levamisole by UV 
spectrophotometric method at λmax 
  
220 nm in phosphate buffer (pH 6.8) 
had good reproducibility and this method was used in the study. The 
correlation coefficient for the standard curve was found to be closer to 1, 
at the concentration range, 2-10 μg/ml, which obeys beer’s lamberts law. 
The regression equation generated was y = 0.085x-0.017. 
Table 2: Data for the standard plot of levamisole in phosphate buffer (pH 6.8) 
S. No. Concentration (μg/ml) Absorbance* 
1 0 0 
2 2 0.139±0.022 
3 4 0.316±0.014 
4 6 0.497±0.024 
5 8 0.676±0.017 
6 10 0.842±0.011 
*mean±SD, n=3, SD: Standard deviation 
 
 
Fig. 1: Standard plot of levamisole in phosphate buffer (pH 6.8, values are expressed as mean±SD, n=3) 
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Fig. 3: FTIR spectrum of optimized formulation 
 
Drug-excipient compatibility studies 
The compatibility of pure drug and excipients were studied by using 
FTIR spectroscopy. From the FTIR spectrum of the drug (fig. 2) and 
drug with the excipients (fig. 3), it was evident that the drug, super 
disintegrants, and other excipients, did not have any interaction with 
each other. The spectrums showed C-S-C stretching of the pure 
levamisole drug (688.97 m-1) and the optimized formulation (755.39 
cm-1) within the literature range of 772-622 cm-1
Evaluation of pre-compression parameters of the powder blend 
 at fingerprint region 
and clearly indicated the compatibility of the pure drug with the 
excipients. 
The data obtained by pre-compression studies were shown in 
table 3. The values for the angle of repose were found in the range 
of 24-26 °. LBD and TBD of various formulations were found in the 
range of 0.42 to 0.54 (gm/cm2) and 0.54 to 0.58 (gm/cm2
 
) 
respectively. Carr’s index of the prepared blends falls in the range 
of 14.26 to 16.82 %. The Hausner's ratio falls in the range of 1.12 
to 1.15. From the result, it was concluded that the powder blends 
had good flow properties and these can be used for tablet 
manufacture.
Table 3: Data for pre-compression parameters 
Formulations Loose bulk density* 
(gm/cm2




Hausner’s ratio* Angle of repose* (Ɵ) 
F 0.4±0.012 1 0.51±0.008 15.12±0.75 1.14±0.74 24.91±0.54 
F 0.52±0.004 2 0.52±0.009 15.52±0.85 1.13±0.81 25.24±0.44 
F 0.54±0.006 3 0.53±0.011 14.10±0.65 1.15±0.78 26.31±0.05 
F 0.42±0.025 4 0.55±0.007 16.27±0.88 1.13±0.07 24.72±0.87 
F 0.45±0.011 5 0.53±0.014 15.30±0.92 1.14±0.08 25.31±0.99 
F 0.46±0.020 6 0.56±0.021 14.26±0.98 1.12±0.12 24.22±0.25 
F 0.47±0.017 7 0.54±0.017 14.19±0.75 1.15±0.54 23.14±0.74 
F 0.51±0.008 8 0.55±0.004 15.18±0.93 1.13±0.48 25.15±0.04 
F 0.53±0.004 9 0.53±0.019 16.82±0.56 1.12±0.88 23.16±0.65 
*mean±SD, n=3, SD: Standard deviation 
 
Evaluation of levamisole chewable tablets 
Weight variation 
The average weights of all the batches of tablets were found within 
the range of 301 mg to 306 mg (table 4). According to official 
guidelines,±5 % is permitted for tablets weighing more than 250 mg 
[30]. Thus all the prepared chewable tablets of levamisole were 
passed weight variation test. The results of the test showed that the 
tablet weights were within the pharmacopoeia limit. 
Hardness 
The hardness of the ten tablets of each batch was checked by using 
Monsanto hardness tester and the data were shown in table 4. The 
results showed that the hardness of the tablets was in the range of 
2.2 to 2.6 kg/cm2
Tablets of each batch were evaluated for percentage friability. The 
average friability of all the formulations lies in the range of 0.41 to 
0.45 %, which was less than 1% as per the official requirement of IP, 
indicating a good mechanical resistance of tablets. Friability less 
than 1% is considered acceptable [31-35]. The data for the 
percentage friability of each batch is shown in table 4. 
Drug content uniformity 
Drug content uniformity studies were performed for the prepared 
formulations. From the studies, it was concluded that all the 
formulations were showing the drug content within 971.4-995.2 
µg/ml after 100 times dilution (table 4). Though it was acceptable, a 
100 % of the drug content was not seen in all the batches. This may be 
due to the segregation of the blend while feeding during tableting [36]. 
In vitro dissolution studies 
, which was within IP limits. 
Thickness 
The thickness of ten tablets of each batch was checked by using Vernier 
Caliper and data are depicted in table 3. The result showed that the 
thickness of the tablet is raging from 3.21 to 3.42 mm (table 4). 
Friability 
From table 5 and fig. 5-6, it was evident that the formulation 
prepared with DRC Indion 234 50 mg showed a maximum 
percentage drug release in 45 min (97.13%). Irrespective of the 
super disintegrant type, the percentage drug release was prolonged 
up to 45 min as the concentration of agent’s increases. When 
compared to all other formulation, the batches with DRC Indion 234 
(F7-F9) showed a better release of the drug (90 % drug release 
within 45 min). This could be due to the properties of DRC Indion 
234, which works by rapid swelling and disintegrating tablets 
rapidly into apparently primary particles [37]. 
Chaudhary et al. 
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Table 4: Data for post-compression parameters 
Formulations Weight variationa Hardness (mg) b (kg/cm2 Thickness) b Friability (mm) a Drug content (%) a (µg/ml) 
F 301 1 2.4 3.32 0.44 982.7 
F 302 2 2.3 3.21 0.32 971.4 
F 301 3 2.6 3.44 0.45 981.6  
F 302 4  2.3 3.22 0.42 962.4 
F 304 5 2.2 3.25 0.41 972.2  
F 302 6 2.6 3.51 0.45 982.4 
F 306 7 2.3 3.21 0.41 971.6 
F 303 8 2.6 3.24 0.44 995.2 
F 303 9 2.2 3.42 0.41 971.4 
amean±SD, n=3; b
 
mean±SD, n=10, SD: Standard deviation 
 
Fig. 4: Dissolution profile for formulations F1-F3 (Sodium Starch Glycolate, values are expressed as mean±SD, n=3) 
 
 
Fig. 5: Dissolution profile for formulations F4-F6 (DRC Indion 204, values are expressed as mean±SD, n=3) 
 
 
Fig. 6: Dissolution profile for formulations F7-F9 (DRC Indion 234, values are expressed as mean±SD, n=3) 
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Table 5: Dissolution data for all the formulations 
Time (min) F1 F2* F3* F4* F5* F6* F7* F8* F9* * 
5 21.14±0.14 22.7±0.65 23.12±0.18 16.4±0.41 16.09±0.98 22.54±0.99 22.54±0.33 20.37±0.22 16.45±0.91 
10 46.58±0.57 41.67±0.98 45.37±0.58 42.87±0.87 43.95±0.47 45.77±0.78 44.67±0.97 42.61±0.40 43.54±0.20 
15 61.87±0.36 63.24±0.25 64.84±0.47 56.84±0.34 54.75±0.39 62.57±0.87 63.57±0.89 59.34±0.98 57.42±0.52 
20 65.27±0.71 69.32±0.69 67.24±0.19 63.57±0.96 59.34±0.55 67.45±0.69 68.41±0.75 62.57±0.92 63.89±0.66 
30 69.24±0.78 73.44±0.57 76.34±1.20 65.57±0.12 65.47±0.77 75.21±0.66 83.64±0.98 67.24±0.74 69.24±0.99 
45 82.25±0.32 86.21±1.25 87.31±0.57 85.21±0.39 78.25±0.66 85.34±0.22 97.13±0.44 92.34±0.88 91.21±0.12 
*mean±SD, n=3, SD: Standard deviation 
 
CONCLUSION 
The current study was focused on the formulation of levamisole 
chewable tablets. Nine batches of levamisole chewable tablets were 
successfully formulated by optimizing the concentration of super 
disintegrants such as sodium starch glycolate, DRC Indion 204, and 
DRC Indion 234. Among the formulations F7 batch showed a 
maximum % drug release i.e., 97.13 % in 45 min hence it is 
considered as an optimized formulation. It was concluded from the 
dissolution studies that the DRC Indion 234 is the best super 
disintegrant irrespective of their concentration for the formulation 
of levamisole chewable tablets when compared to sodium starch 
glycolate and DRC Indion 204. 
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